 |
|
JAMA-EXPRESS
Varenicline, an  4 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation
A Randomized Controlled Trial
David Gonzales, PhD;
Stephen I. Rennard, MD;
Mitchell Nides, PhD;
Cheryl Oncken, MD;
Salomon Azoulay, MD;
Clare B. Billing, MS;
Eric J. Watsky, MD;
Jason Gong, MD;
Kathryn E. Williams, PhD;
Karen R. Reeves, MD; for the Varenicline Phase 3 Study Group
JAMA. 2006;296:47-55.
Context The  4 2 nicotinic acetylcholine receptors (nAChRs) are linked to the reinforcing effects of nicotine and maintaining smoking behavior. Varenicline, a novel 42 nAChR partial agonist, may be beneficial for smoking cessation.
Objective To assess efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion SR) and placebo.
Design, Setting, and Participants Randomized, double-blind, parallel-group, placebo- and active-treatment–controlled, phase 3 clinical trial conducted at 19 US centers from June 19, 2003, to April 22, 2005. Participants were 1025 generally healthy smokers ( 10 cigarettes/d) with fewer than 3 months of smoking abstinence in the past year, 18 to 75 years old, recruited via advertising.
Intervention Participants were randomly assigned in a 1:1:1 ratio to receive brief counseling and varenicline titrated to 1 mg twice per day (n = 352), bupropion SR titrated to 150 mg twice per day (n = 329), or placebo (n = 344) orally for 12 weeks, with 40 weeks of nondrug follow-up.
Main Outcome Measures Primary outcome was the exhaled carbon monoxide–confirmed 4-week rate of continuous abstinence from smoking for weeks 9 through 12. A secondary outcome was the continuous abstinence rate for weeks 9 through 24 and weeks 9 through 52.
Results For weeks 9 through 12, the 4-week continuous abstinence rates were 44.0% for varenicline vs 17.7% for placebo (odds ratio [OR], 3.85; 95% confidence interval [CI], 2.70-5.50; P<.001) and vs 29.5% for bupropion SR (OR, 1.93; 95% CI, 1.40-2.68; P<.001). Bupropion SR was also significantly more efficacious than placebo (OR, 2.00; 95% CI, 1.38-2.89; P<.001). For weeks 9 through 52, the continuous abstinence rates were 21.9% for varenicline vs 8.4% for placebo (OR, 3.09; 95% CI, 1.95-4.91; P<.001) and vs 16.1% for bupropion SR (OR, 1.46; 95% CI, 0.99-2.17; P = .057). Varenicline reduced craving and withdrawal and, for those who smoked while receiving study drug, smoking satisfaction. No sex differences in efficacy for varenicline were observed. Varenicline was safe and generally well tolerated, with study drug discontinuation rates similar to those for placebo. The most common adverse events for participants receiving active-drug treatment were nausea (98 participants receiving varenicline [28.1%]) and insomnia (72 receiving bupropion SR [21.9%]).
Conclusion Varenicline was significantly more efficacious than placebo for smoking cessation at all time points and significantly more efficacious than bupropion SR at the end of 12 weeks of drug treatment and at 24 weeks.
Trial Registration clinicaltrials.gov Identifier: NCT00141206
Author Affiliations: Smoking Cessation Center, Department of Medicine, Oregon Health & Science University, Portland (Dr Gonzales); Pulmonary Division, University of Nebraska Medical Center, Omaha (Dr Rennard); Los Angeles Clinical Trials, Los Angeles, Calif (Dr Nides); Department of Medicine, University of Connecticut Health Center, Farmington (Dr Oncken); Pfizer Global Research and Development, Groton, Conn (Drs Azoulay, Watsky, Gong, Williams, and Reeves and Mr Billing).
RELATED LETTER
Efficacy of Varenicline for Smoking Cessation
Alain Dervaux, Mostafa Kanit, and Xavier Laqueille
JAMA. 2006;296(21):2555.
EXTRACT
| FULL TEXT
RELATED ARTICLES
Efficacy of Varenicline, an 42 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial
Douglas E. Jorenby, J. Taylor Hays, Nancy A. Rigotti, Salomon Azoulay, Eric J. Watsky, Kathryn E. Williams, Clare B. Billing, Jason Gong, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):56-63.
ABSTRACT
| FULL TEXT
Effect of Maintenance Therapy With Varenicline on Smoking Cessation: A Randomized Controlled Trial
Serena Tonstad, Philip Tønnesen, Peter Hajek, Kathryn E. Williams, Clare B. Billing, Karen R. Reeves, and for the Varenicline Phase 3 Study Group
JAMA. 2006;296(1):64-71.
ABSTRACT
| FULL TEXT
Varenicline for Smoking Cessation: Definite Promise, But No Panacea
Robert C. Klesges, Karen C. Johnson, and Grant Somes
JAMA. 2006;296(1):94-95.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
{blacktriangledown}Varenicline for smoking cessation
DTB 2008;46:33-36.
ABSTRACT
| FULL TEXT
Approach to chronic obstructive pulmonary disease in primary care
Todd et al.
cfp 2008;54:706-711.
ABSTRACT
| FULL TEXT
Multidisciplinary Care of the Patient with Chronic Obstructive Pulmonary Disease
Kuzma et al.
Proc Am Thorac Soc 2008;5:567-571.
ABSTRACT
| FULL TEXT
How to implement a smoke-free policy
Cormac and McNally
Adv. Psychiatr. Treat. 2008;14:198-207.
ABSTRACT
| FULL TEXT
Gender and Chronic Obstructive Pulmonary Disease: Why It Matters
Han et al.
Am. J. Respir. Crit. Care Med. 2007;176:1179-1184.
ABSTRACT
| FULL TEXT
The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline
Hollis et al.
Tobacco Control 2007;16:i53-i59.
ABSTRACT
| FULL TEXT
Pharmacologic Therapy: Novel Approaches for Chronic Obstructive Pulmonary Disease
Bailey and Tashkin
Proc Am Thorac Soc 2007;4:543-548.
ABSTRACT
| FULL TEXT
A Double-blind, Placebo-Controlled, Randomized Trial of Bupropion for Smoking Cessation in Primary Care
Fossati et al.
Arch Intern Med 2007;167:1791-1797.
ABSTRACT
| FULL TEXT
Lung Cancer Chemoprevention: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition)
Gray et al.
Chest 2007;132:56S-68S.
ABSTRACT
| FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:652-726.
FULL TEXT
Exacerbation of Schizophrenia by Varenicline
FREEDMAN
Am. J. Psychiatry 2007;164:1269-1269.
FULL TEXT
Varenicline, an {alpha}4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking
Steensland et al.
Proc. Natl. Acad. Sci. USA 2007;104:12518-12523.
ABSTRACT
| FULL TEXT
Update in General Internal Medicine
Harrington and Munekata
ANN INTERN MED 2007;147:104-116.
FULL TEXT
Varenicline: The newest agent for smoking cessation
Potts and Garwood
Am J Health Syst Pharm 2007;64:1381-1384.
ABSTRACT
| FULL TEXT
State of the Art Reviews: Smoking Cessation: A Review of Treatment Considerations
Sullivan et al.
AMERICAN JOURNAL OF LIFESTYLE MEDICINE 2007;1:201-213.
ABSTRACT
Alcohol history and smoking cessation in nicotine replacement therapy, bupropion sustained release and varenicline trials: a review
Leeman et al.
Alcohol Alcohol 2007;42:196-206.
ABSTRACT
| FULL TEXT
Update in Lung Cancer 2006
Dubey and Powell
Am. J. Respir. Crit. Care Med. 2007;175:868-874.
FULL TEXT
Comment: Oral Varenicline for Smoking Cessation
Gonzales et al.
The Annals of Pharmacotherapy 2007;41:720-721.
FULL TEXT
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy
Tonnesen et al.
Eur Respir J 2007;29:390-417.
ABSTRACT
| FULL TEXT
A research agenda for assessing the potential contribution of genomic medicine to tobacco control
Hall
Tobacco Control 2007;16:53-58.
ABSTRACT
| FULL TEXT
Preclinical Development and Clinical Implementation of Treatments for Substance Abuse Disorders
Pechnick et al.
Focus 2007;5:151-162.
ABSTRACT
| FULL TEXT
Bibliography for Substance Abuse: Diagnosis and Treatment
Focus 2007;5:184-186.
FULL TEXT
Varenicline (Chantix) for Tobacco Dependence
Obstet Gynecol 2007;109:192-193.
FULL TEXT
Oral Varenicline for Smoking Cessation
Zierler-Brown and Kyle
The Annals of Pharmacotherapy 2007;41:95-99.
ABSTRACT
| FULL TEXT
Efficacy of Varenicline for Smoking Cessation
Dervaux et al.
JAMA 2006;296:2555-2555.
FULL TEXT
Efficacy of Varenicline for Smoking Cessation--Reply
Jorenby et al.
JAMA 2006;296:2555-2556.
FULL TEXT
Trials that Matter: Varenicline: A Designer Drug to Help Smokers Quit.
Schroeder and Sox
ANN INTERN MED 2006;145:784-785.
FULL TEXT
Promising New Drug Could Help Smokers Kick the Habit
Holman
DOC News 2006;3:16-16.
FULL TEXT
Smoking Cessation With Varenicline, a Selective {alpha}4beta2 Nicotinic Receptor Partial Agonist: Results From a 7-Week, Randomized, Placebo- and Bupropion-Controlled Trial With 1-Year Follow-up.
Nides et al.
Arch Intern Med 2006;166:1561-1568.
ABSTRACT
| FULL TEXT
Is a New Smoking-Cessation Drug on the Horizon?
Journal Watch Cardiology 2006;2006:5-5.
FULL TEXT
New Drug for Smoking Cessation
JWatch General 2006;2006:2-2.
FULL TEXT
Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial.
Tonstad et al.
JAMA 2006;296:64-71.
ABSTRACT
| FULL TEXT
Varenicline for smoking cessation: definite promise, but no panacea.
Klesges et al.
JAMA 2006;296:94-95.
FULL TEXT
|
